Cardiff Oncology Announces Positive Results from Phase 1b Clinical Trial of Onvansertib in Combination with Paclitaxel for Metastatic Triple-Negative Breast Cancer

Summary

Cardiff Oncology announced positive results from a Phase 1b clinical trial of onvansertib in combination with paclitaxel for treating metastatic triple-negative breast cancer (mTNBC). The trial demonstrated an objective response rate of 40% at the highest dose, with the combination being well-tolerated and exhibiting manageable toxicity. The trial was led by the Dana-Farber Cancer Institute and involved patients with prior chemotherapy experience. These findings support further exploration of onvansertib in treating mTNBC and other cancers.GlobeNewswire

Impact Analysis

The positive clinical trial results for Cardiff Oncology’s onvansertib indicate a significant product milestone, potentially enhancing the company’s competitive position in the oncology drug market. First-order effects include improved growth prospects due to the drug’s efficacy and safety, potentially expanding its use in treating mTNBC and other cancers. This could lead to increased investor interest and funding opportunities for further trials. However, risks include the regulatory hurdles and competition from other oncology treatments. Second-order effects could involve increased attention from peer companies focusing on similar cancer treatments, potentially affecting Cardiff Oncology’s market share and partnerships. Investors might consider opportunities in Cardiff Oncology’s stock, anticipating the commercial viability of onvansertib, while being mindful of the associated risks.GlobeNewswire+ 2